Using the ar-v7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility

HIGHLIGHTS

• who: Astex Pharmaceuticals et al. from the University labs to test for AR-, positivityExtra Newcastle upon Tyne Hospitals NHS Foundation Trust, upon Tyne, Tyne and Wear, HD, UK have published the paper: Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility, in the Journal: (JOURNAL) of 10/01/2023
• what: Due to a number of issues the trial was not completed successfully the authors aim to discuss and share lessons learned herein. view view view view version 2 (revision) version 1 02 2022 1. The aim was to . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.